Stock Analyst Note
Ypsomed Earnings: Strong Auto-Injector Sales Lift Margins and Guidance; Raise Fair Value Estimate
Ypsomed's core delivery systems business delivered 17.5% sales growth in the first half of fiscal 2026/27, driven by auto-injector sales, which supported a favorable product mix and EBIT margin of nearly 36% despite ongoing capacity expansion. Shares rose 5% in trading on Nov. 11.